奈达铂联合放疗治疗局部晚期鼻咽癌的临床观察  

The clinical observation on treatment of nedaplatin combined with radiotherapy for locally advanced nasopharyngeal carcinoma

作　　者：沈泽天[1] 武新虎[1] 李兵[1] 沈君姝[1] 王振[1] 李静[1] 朱锡旭[1] 

机构地区：[1]南京军区南京总医院放射治疗科,南京210002

出　　处：《癌症进展》2014年第4期399-402,408,共5页Oncology Progress

摘　　要：目的探讨奈达铂联合放疗治疗局部晚期鼻咽癌的临床疗效及毒副作用。方法入组2010年1月至2012年1月在我院诊治的60例局部晚期鼻咽癌患者,给予同期放化疗治疗,随机分为对照组(顺铂)和观察组(奈达铂),每组各30例,对两组近期疗效、远期疗效、毒副作用进行观察和比较。结果观察组与对照组的鼻咽部肿瘤、颈部淋巴结完全缓解率(20.0%vs 16.7%;66.7%vs 60.0%)和部分缓解率(76.7%vs 76.7%;33.3%vs 40.0%)差异无统计学意义(P>0.05);与对照组相比,观察组骨髓抑制(23.3%vs 50.0%)、恶心呕吐(36.7%vs 76.7%)发生率显著降低,差异有统计学意义(P<0.05)。结论奈达铂联合放疗治疗局部晚期鼻咽癌的毒副作用少,安全性相对较高,值得临床推广。Objective To study the clinical efficacy and toxicity of the treatment of nedaplatin combined with radiotherapy for locally advanced nasopharyngeal carcinoma. Method The 60 patients with locally advanced nasopharyngeal carcinoma treated by chemotherapy treatment in our hospital from Jan, 2010 to Jan, 2012 were randomized into control group（cisplatin） and observation group（nedaplatin）, with 30 patients in each. The recent efficacy,long-term efficacy, toxicity and side effects in both groups were observed and then compared. Result For the observation group, the difference of CR rate（20.0% vs 16.7%; 66.7% vs 60.0%） and the PR rate（76.7% vs 76.7%;33.3% vs 40.0%） of nasopharyngeal carcinoma and cervical lymph node were not statistically different（P〉0.05） compared with the control group; While the incidence of bone marrow suppression（23.3% vs 50.0%）,and nausea and vomiting（36.7% vs 76.7%）were significantly reduced（P〈0.05）. Conclusion For locally advanced nasopharyngeal carcinoma, nedaplatin combined with radiotherapy causes minor toxicity and less side effects, which is relatively safe and is worthy of clinical promotion.

关 键 词：奈达铂 放疗 晚期鼻咽癌 毒副作用 

分 类 号：R739.6[医药卫生—肿瘤]